Research programme: xB3 platform based therapeutics - biOasis Technologies

Drug Profile

Research programme: xB3 platform based therapeutics - biOasis Technologies

Alternative Names: xB3 001; xB3 002; xB3 003

Latest Information Update: 06 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator biOasis Technologies
  • Class Antineoplastics; Antiparkinsonians; Neuroprotectants
  • Mechanism of Action Gene modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Brain metastases; Glioblastoma; Parkinson's disease

Most Recent Events

  • 06 Nov 2017 biOasis Technologies has patent protection for Transcend and xB3 delivery platform technology (biOasis Technologies website, November 2017)
  • 06 Nov 2017 Preclinical trials in Brain metastases in Canada before November 2017 (biOasis pipeline, November 2017)
  • 06 Nov 2017 Preclinical trials in Glioblastoma in Canada before November 2017 (biOasis pipeline, November 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top